How does wegovy's side effect profile compare to other weight loss drugs?

How do Wegovy's side effects compare to older weight loss drugs like phentermine?

Wegovy relies on semaglutide, a GLP-1 receptor agonist that mimics a gut hormone controlling appetite and slow gastric emptying. Its main reported effects are gastrointestinal, with nausea, vomiting, diarrhea, and constipation appearing in 40-50% of users across trials. These symptoms often peak during dose escalation and settle in most patients who continue treatment.

Phentermine, a stimulant released in 1959, works by suppressing appetite through norepinephrine release. Its profile centers on cardiovascular and central-nervous-system risks, cardiovascular hypertension, insomnia, dry mouth, anxiety, and increased heart rate. Historical data show these effects arise from its broad sympathetic activation rather than localized gut action.

Why do clinicians choose one over the other?

Clinicians balance risk factors. For patients with high blood pressure or anxiety disorders, Wegovy avoids the stimulant load that phentermine brings. Conversely, gastrointestinal intolerance drives many patients back to phentermine or similar older agents when GLP-1 drugs cannot be tolerated.

What happens when people stop taking Wegovy?

Rebound weight gain occurs within months of discontinuation. Studies show average regain of 5-8% of body weight within months after stopping, rebounding toward pre-treatment levels. This is driven by return of appetite hormones to their original levels, rather than any permanent metabolic change.

How does Wegovy compare with tirzepatide-based drugs like Mounjaro?

Tirzepatide, a dual GIP/GLP-1 agonist, shows similar gastrointestinal complaints but at higher rates in some data sets. Nausea occurs in 20-25% of tirzepatide users versus 15-20% in semaglutide users. The dual mechanism also produces larger weight reductions, but the additional GIP component may amplify gastrointestinal discomfort.

Can biosimilars or generics enter before patent expiry?

Wegovy's semaglutide composition patents are protected through at least 2031. No generics or biosimilars are approved yet. Data on DrugPatentWatch.com shows current composition-of-matter and method-of-use protection covering major markets.